Nuveen
CCCC icon

Nuveen’s C4 Therapeutics CCCC Stock Holding History

Nuveen’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
+484,010
New +$1.66M ﹤0.01% 2519
2025
Q2 		– Sell
-192,424
Closed -$308K – 3292
2025
Q1 		$308K Hold
192,424
– – ﹤0.01% 3038
2024
Q4 		$693K Buy
192,424
+11,571
+6% +$57.5K ﹤0.01% 2863
2024
Q3 		$1.03M Sell
180,853
-250,160
-58% -$1.51M ﹤0.01% 2748
2024
Q2 		$1.99M Buy
+431,013
New +$2.57M ﹤0.01% 2400
2023
Q2 		– Sell
-356,609
Closed -$1.12M – 3221
2023
Q1 		$1.12M Sell
356,609
-20,915
-6% -$123K ﹤0.01% 2571
2022
Q4 		$2.23M Sell
377,524
-24,360
-6% -$202K ﹤0.01% 2342
2022
Q3 		$3.52M Sell
401,884
-6,175
-2% -$64.1K ﹤0.01% 2101
2022
Q2 		$3.08M Sell
408,059
-12,395
-3% -$109K ﹤0.01% 2213
2022
Q1 		$9.77M Buy
420,454
+157,052
+60% +$3.81M ﹤0.01% 1654
2021
Q4 		$7.47M Sell
263,402
-43,934
-14% -$1.74M ﹤0.01% 1858
2021
Q3 		$15.4M Buy
307,336
+106,944
+53% +$4.58M ﹤0.01% 1462
2021
Q2 		$7.58M Buy
200,392
+97,078
+94% +$3.48M ﹤0.01% 2021
2021
Q1 		$3.82M Buy
103,314
+78,690
+320% +$3.13M ﹤0.01% 2300
2020
Q4 		$816K Buy
+24,624
New +$714K ﹤0.01% 2879

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's CCCC Position: Q2 2026 in Review

Nuveen opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 484,010 shares worth $2.26M. The stake represents ﹤0.01% of the portfolio and ranks #2519 among its holdings. This is a return to the name: Nuveen previously reported a position in CCCC as recently as Q1 2025.

Nuveen first reported a position in CCCC in Q4 2020 and has held it in 15 quarters since. The position peaked at $15.4M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Nuveen held 484,010 shares of C4 Therapeutics worth $2.26M as of Q2 2026.
  • C4 Therapeutics was a new Nuveen position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2519 holding.
  • Nuveen first reported a position in C4 Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Nuveen's C4 Therapeutics position peaked at $15.4M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.